home / stock / celuw / celuw news

CELUW News and Press, Celularity Inc. Warrant

Stock Information
Company Name: Celularity Inc. Warrant
Stock Symbol: CELUW
Market: NASDAQ
Website: celularity.com
Menu
CELUW CELUW Quote CELUW Short CELUW News CELUW Articles CELUW Message Board
Get CELUW Alerts

News, Short Squeeze, Breakout and More Instantly...
CELUW - Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

FLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it presented in vivo ...
CELUW - Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on May 21, 2024, the Compa...

CELUW - Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that the Journa...

CELUW - Celularity Inc. to Host Investor and Analyst Research & Development Day

FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today it will host ...
CELUW - Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on April 17, 2024, the C...

CELUW - Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024

FLORHAM PARK, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that its abstract entitled “Emerging...

CELUW - Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Expects the First Quarter of 2024 will be the 4 th consec utive quarter of both sequential and quarter-on-quarter net sales growth Implements plan to reduce 2024 selling, general & administrative expenses (SG&A), executive cash compensation, reinforces management...
CELUW - Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

FLORHAM PARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from it...

CELUW - Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that the U.S. Centers for Medi...

CELUW - Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it has submitted a reques...
Next 10